LivaNova PLC (LIVN) Shares Sold by Gideon Capital Advisors Inc.

Share on StockTwits

Gideon Capital Advisors Inc. lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 21.3% in the fourth quarter, Holdings Channel reports. The fund owned 3,237 shares of the company’s stock after selling 875 shares during the quarter. Gideon Capital Advisors Inc.’s holdings in LivaNova were worth $296,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Federated Investors Inc. PA increased its holdings in shares of LivaNova by 1,514.3% in the third quarter. Federated Investors Inc. PA now owns 557,386 shares of the company’s stock valued at $69,099,000 after purchasing an additional 522,859 shares during the last quarter. BlackRock Inc. boosted its position in shares of LivaNova by 7.3% during the third quarter. BlackRock Inc. now owns 5,787,930 shares of the company’s stock worth $717,530,000 after buying an additional 394,915 shares during the period. Morgan Stanley boosted its position in shares of LivaNova by 230.8% during the third quarter. Morgan Stanley now owns 510,953 shares of the company’s stock worth $63,343,000 after buying an additional 356,476 shares during the period. Rehmann Capital Advisory Group boosted its position in shares of LivaNova by 12,226.6% during the third quarter. Rehmann Capital Advisory Group now owns 303,974 shares of the company’s stock worth $2,452,000 after buying an additional 301,508 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of LivaNova by 140.0% during the third quarter. Marshall Wace LLP now owns 350,899 shares of the company’s stock worth $43,501,000 after buying an additional 204,684 shares during the period. 89.50% of the stock is owned by institutional investors and hedge funds.

In other LivaNova news, insider Alistair Simpson sold 450 shares of the firm’s stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $90.10, for a total value of $40,545.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel Jeffrey Moore sold 1,500 shares of the firm’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $100.44, for a total value of $150,660.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,950 shares of company stock valued at $557,435. 0.41% of the stock is currently owned by company insiders.

NASDAQ:LIVN opened at $95.62 on Friday. The firm has a market capitalization of $4.62 billion, a P/E ratio of 30.16, a P/E/G ratio of 2.75 and a beta of 0.87. LivaNova PLC has a 12-month low of $79.96 and a 12-month high of $131.54. The company has a quick ratio of 0.76, a current ratio of 1.07 and a debt-to-equity ratio of 0.09.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 27th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.02. The firm had revenue of $297.00 million during the quarter, compared to analyst estimates of $294.98 million. LivaNova had a positive return on equity of 9.64% and a negative net margin of 17.11%. LivaNova’s revenue was up 6.7% compared to the same quarter last year. During the same period last year, the business posted $0.88 earnings per share. Equities research analysts predict that LivaNova PLC will post 3.33 earnings per share for the current year.

Several research firms have recently commented on LIVN. BTIG Research restated a “hold” rating on shares of LivaNova in a research report on Tuesday, March 5th. BidaskClub lowered LivaNova from a “buy” rating to a “hold” rating in a research report on Thursday, February 28th. Needham & Company LLC restated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of LivaNova in a research report on Wednesday, February 27th. Zacks Investment Research upgraded LivaNova from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, ValuEngine lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 28th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $128.75.

ILLEGAL ACTIVITY NOTICE: “LivaNova PLC (LIVN) Shares Sold by Gideon Capital Advisors Inc.” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4223909/livanova-plc-livn-shares-sold-by-gideon-capital-advisors-inc.html.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Recommended Story: Stock Split

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Southwest Airlines Co  Shares Bought by Boyer & Corporon Wealth Management LLC
Southwest Airlines Co Shares Bought by Boyer & Corporon Wealth Management LLC
GoPro Inc  Shares Sold by BNP Paribas Arbitrage SA
GoPro Inc Shares Sold by BNP Paribas Arbitrage SA
BNP Paribas Arbitrage SA Grows Holdings in Enanta Pharmaceuticals Inc
BNP Paribas Arbitrage SA Grows Holdings in Enanta Pharmaceuticals Inc
Walmart  Price Target Raised to $107.00 at UBS Group
Walmart Price Target Raised to $107.00 at UBS Group
Textainer Group  Upgraded to Strong-Buy by Zacks Investment Research
Textainer Group Upgraded to Strong-Buy by Zacks Investment Research
Walmart Inc  Shares Bought by Bank of Stockton
Walmart Inc Shares Bought by Bank of Stockton


© 2006-2019 Ticker Report